You are here

FDA Panel Reschedules Review of Troubled Muscular Dystrophy Drug Eteplirsen

Analysts see little chance of approval

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee has announced that it will discuss the new drug application for eteplirsen (Sarepta Therapeutics) on April 25––nearly three months after the original action date. Sarepta is seeking approval for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

On January 15, FDA staff said they were unconvinced about eteplirsen’s efficacy and trial design, a day after the agency rejected rival drug drisapersen (Kyndrisa, BioMarin Pharmaceutical) for insufficient efficacy.

There are no FDA-approved drugs for DMD, and pressure has been mounting on the FDA to quickly approve treatments.

Three years ago, Sarepta’s CEO claimed that the company was making progress in convincing the FDA to accept dystrophin production as a surrogate marker that could be used for early approval. But Sarepta’s data on walking distance in boys were taken from a tiny study, and an internal review by FDA staff dismissed the company’s findings out of hand.

As of now, analysts give eteplirsen little chance of being approved when it comes up for a formal decision.

Sources: Reuters; March 10, 2016; and FierceBiotech; March 10, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs